Related content

JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 9, 2012-01 ,pp. : 1098-1109

Bentham Science Publishers

Access to resources Recommend Favorite

The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review)

By    

International Journal of Oncology, Vol. 44, Iss. 4, 2014-01 ,pp. : 1032-1040

Spandidos Publications

Access to resources Recommend Favorite

Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma

By                

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 498-502

Spandidos Publications

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 3, 2013-03 ,pp. : 476-482

Bentham Science Publishers

Access to resources Recommend Favorite

Hepatocyte Growth Factor Activation Inhibitors – Therapeutic Potential in Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 1, 2010-01 ,pp. : 47-57

Bentham Science Publishers

Access to resources Recommend Favorite